Monthly Archives: June 2011

Supreme Court Ruling Makes Generics More Dangerous

By Ben Comer | Published: June 23, 2011
Today’s Supreme Court ruling on Pliva v. Mensing, which held that generic drug companies are not responsible for updating drug labels in light of new safety concerns, makes taking generic drugs a riskier proposition for consumers, Justice Sonia Sotomayor wrote in her dissenting opinion. Justices Stephen Breyer, Elena Kagan and Ruth Bader Ginsburg also dissented [...]
Posted in Corporate Responsibility, Legal | Tagged , | 1 Comment

DIA: Social Media Guidelines are DDMAC’s "Highest Priority"

By Ben Comer | Published: June 22, 2011
Tom Abrams, director of FDA’s Division (soon to be Office) of Drug Marketing, Advertising & Communications (DDMAC), said that publishing social media guidelines for industry is the division’s “highest priority,” and that the document will be “published as soon as it’s vetted.”
Posted in Advertising, E-Media, FDA, Marketing, Meetings, Regulatory, Strategy, Technology, patient education, social media | Tagged , , | 1 Comment

DIA: Does Six Sigma Stifle R&D Innovation?

By Ben Comer | Published: June 21, 2011
Can the management style known as Six Sigma help improve the probability of a drug’s commercial success, or do its black-belted acolytes punch holes in the creative process needed for innovative R&D discovery?
Posted in IP, R&D, Strategy, leadership | Tagged , , , | 4 Comments

Pharma “Channels” Patient Engagement

By Jennifer Ringler | Published: June 21, 2011
New disease-specific television networks shown in physicians’ offices provide education for patients and advertising at the point of contact for pharma companies. What if pharma companies had one last chance to reach patients, just before they walked into the exam room to speak to their physicians? What if the very last word a patient heard before [...]
Posted in Advertising, Marketing, Patient Communication, Technology, healthcare, patient education | 1 Comment

Pharma Complexity Is Leading to Loss of Profits

By Guest Blogger | Published: June 15, 2011
It will take far more than factory closures to simplify the pharma industry, write Melvin Jay and Professor Simon Collinson. When pharmaceutical giant Novartis announced it was likely to close its West Sussex (UK) factory, it came as no surprise to the pharmaceutical industry — as Pfizer, AstraZeneca and Glaxo had done the same. While these [...]
Posted in Strategy | Tagged , , , | 3 Comments